https://www.thepharmaletter.com/article/550-million-for-phase-iii-trial-of-pulmonary-tb-vaccine
0
0
A decades-long program to develop the first new vaccine for pulmonary tuberculosis in a century has received a half-billion dollar funding boost. British drugmaker GSK (LSE: GSK) has been working on the jab, dubbed M72, since it picked up rights to the candidate through its 2005 purchase of American biotech Corixa. While the vaccine has shown 54% effectiveness in a Phase II trial enrolling around ... - The Pharma Letter
6/29/23 at 7:14pm
Organization
The Pharma Letter
Authors
Details
94 words
Summarize
Health Pharmaceuticals & Biotech GSK dollar funding boost M72 London Stock Exchange Corixa
A decades-long program to develop the first new vaccine for pulmonary tuberculosis in a century has received a half-billion dollar funding boost.
Create an account or login to join the discussion